News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
The Group will continue to make proactive investments of its management resources in the life science business
The new facility is scheduled to start operation in the first half of 2024
The ultrasound products manufactured in the new manufacturing facility will be sold under the brand name SonoRad, and are designed for large hospitals, healthcare institutions and individual radiology centres
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)